Neurocrine Biosciences Inc
NASDAQ:NBIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
US |
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry.
Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.
Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry.
Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.
Revenue Growth: Neurocrine reported over $2.8 billion in total product sales for 2025, up 22% year-over-year, driven by strong performance of INGREZZA and a successful CRENESSITY launch.
INGREZZA Strength: INGREZZA generated just over $2.5 billion in revenue, up 9% YoY, with record new and total patient starts and double-digit volume growth.
CRENESSITY Launch: CRENESSITY exceeded expectations with over $300 million in first-year sales and reached roughly 10% of the addressable classic CAH patient population.
2026 Guidance: INGREZZA 2026 revenue is guided at $2.7–2.8 billion, representing approximately 10% growth, with stable net pricing expected.
Profitability: Neurocrine delivered roughly $850 million in operating income and maintained approximately 30% operating margin in 2025, growing its cash position to $2.5 billion.
Pipeline Progress: The company achieved its Phase I–III objectives in 2025, with multiple late-stage neuropsychiatry programs advancing and new studies initiated, setting up a data-rich 2027.
CRENESSITY Upside: Management remains highly confident in CRENESSITY becoming a blockbuster but is not providing formal 2026 sales guidance due to ongoing market learning.
